-- Accenture (ACN) said Thursday it has invested in Iridius, an enterprise artificial intelligence infrastructure company designing compliant solutions for regulated industries, including life sciences.
Financial terms of the investment were not disclosed.
The companies also entered into a partnership to build end-to-end compliance workflows across the pharmaceutical value chain to scale AI adoption, Accenture said.
The collaboration aims to accelerate clinical timelines and reduce manual compliance work by integrating Iridius' regulatory technology into enterprise operations, Accenture added.
Shares of the company were down about 6.8% in Thursday trading.
Price: $177.00, Change: $-13.11, Percent Change: -6.89%